PL1644412T5 - Modyfikowane fragmenty Fab przeciwciała - Google Patents

Modyfikowane fragmenty Fab przeciwciała

Info

Publication number
PL1644412T5
PL1644412T5 PL04743158T PL04743158T PL1644412T5 PL 1644412 T5 PL1644412 T5 PL 1644412T5 PL 04743158 T PL04743158 T PL 04743158T PL 04743158 T PL04743158 T PL 04743158T PL 1644412 T5 PL1644412 T5 PL 1644412T5
Authority
PL
Poland
Prior art keywords
fab fragments
modified antibody
antibody fab
modified
fragments
Prior art date
Application number
PL04743158T
Other languages
English (en)
Other versions
PL1644412T3 (pl
Inventor
David Paul Humphreys
Sam Philip Heywood
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33566544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1644412(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0315457.2A external-priority patent/GB0315457D0/en
Priority claimed from GB0319588A external-priority patent/GB0319588D0/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of PL1644412T3 publication Critical patent/PL1644412T3/pl
Publication of PL1644412T5 publication Critical patent/PL1644412T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
PL04743158T 2003-07-01 2004-07-01 Modyfikowane fragmenty Fab przeciwciała PL1644412T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0315457.2A GB0315457D0 (en) 2003-07-01 2003-07-01 Biological products
GB0319588A GB0319588D0 (en) 2003-08-20 2003-08-20 Biological products
EP04743158.0A EP1644412B2 (en) 2003-07-01 2004-07-01 Modified antibody fab fragments
PCT/GB2004/002810 WO2005003169A2 (en) 2003-07-01 2004-07-01 Modified antibody fab fragments

Publications (2)

Publication Number Publication Date
PL1644412T3 PL1644412T3 (pl) 2016-02-29
PL1644412T5 true PL1644412T5 (pl) 2019-01-31

Family

ID=33566544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04743158T PL1644412T5 (pl) 2003-07-01 2004-07-01 Modyfikowane fragmenty Fab przeciwciała

Country Status (14)

Country Link
US (1) US7989594B2 (pl)
EP (1) EP1644412B2 (pl)
JP (1) JP2007536898A (pl)
AU (1) AU2004253738A1 (pl)
CA (1) CA2527020A1 (pl)
CY (1) CY1116913T1 (pl)
DK (1) DK1644412T4 (pl)
ES (1) ES2551439T5 (pl)
HR (1) HRP20151252T4 (pl)
HU (1) HUE026278T2 (pl)
PL (1) PL1644412T5 (pl)
PT (1) PT1644412E (pl)
SI (1) SI1644412T2 (pl)
WO (1) WO2005003169A2 (pl)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026260T2 (en) 2003-11-21 2016-06-28 Ucb Biopharma Sprl A method for treating multiple sclerosis by inhibiting IL-17 activity
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
ES2382879T3 (es) 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
SI1960430T1 (sl) 2005-12-09 2015-01-30 Ucb Pharma, S.A. Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
ME00832B (me) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
AU2008261042A1 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of CH1 domain
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
WO2009085106A1 (en) * 2007-12-27 2009-07-09 Duke University Resin assisted capture of cysteine-modified proteins/peptides and determination of presence and location of modification
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
NZ594315A (en) 2009-02-17 2013-05-31 Ucb Pharma Sa Antibody molecules having specificity for human ox40
ES2700442T3 (es) 2009-02-25 2019-02-15 Ucb Biopharma Sprl Método para producir anticuerpos
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
US8859294B2 (en) * 2010-03-17 2014-10-14 Panasonic Corporation Method for binding a protein consisting of protein A or consisting of at least one domain of the A to E domains of the protein A to the substrate
JP4987165B2 (ja) * 2010-03-17 2012-07-25 パナソニック株式会社 プロテインａ、またはプロテインａのａ〜ｅドメインの少なくとも１つからなるタンパク質を基板の表面に結合させる方法
ES2717883T3 (es) 2010-03-25 2019-06-26 Ucb Biopharma Sprl Moléculas de DVD-LG estabilizadas con disulfuro
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
PL2758432T3 (pl) 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
WO2013068571A1 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
EP2785839A2 (en) 2011-11-30 2014-10-08 University of Bremen Expression of mirnas in placental tissue
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
EP2759602A1 (en) 2013-01-25 2014-07-30 Charité - Universitätsmedizin Berlin Non-invasive prenatal genetic diagnostic methods
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP6851322B2 (ja) 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
DK3359688T3 (da) 2015-10-05 2021-08-23 Biogen Ma Inc Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
KR20180098671A (ko) 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
GB201602414D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
CA3022494A1 (en) 2016-05-01 2017-11-09 Ucb Biopharma Sprl Affinity engineered serum protein carrier binding domain
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
EP3565841A1 (en) * 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
EP3572498A4 (en) 2017-01-18 2020-11-18 Shinko Chemical Co., Ltd. CHEMICAL SUBSTANCES EVALUATION SYSTEM AND CHEMICAL SUBSTANCES EVALUATION METHOD
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CN111278459A (zh) 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法
DK3630143T5 (da) 2017-06-01 2024-09-02 Akamis Bio Ltd Onkolytisk virus og fremgangsmåde
US20200165347A1 (en) 2017-06-30 2020-05-28 Aslan Pharmaceuticals Pte Ltd Method of treatment using il-13r antibody
EP3679129A1 (en) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. A method of intracellular delivery
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US20210095006A1 (en) 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
MX2020013808A (es) 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
WO2020036867A1 (en) 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
CN113677708A (zh) 2019-03-26 2021-11-19 亚狮康私人有限公司 采用抗il13r抗体或其结合片段的治疗
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
BR112022002067A2 (pt) 2019-08-08 2022-06-14 Regeneron Pharma Formatos de molécula de ligação ao antígeno
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
MX2022005330A (es) 2019-11-05 2022-05-26 Regeneron Pharma Moleculas de union multiespecificas con scfv en el extremo nterminal.
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
WO2021160269A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
WO2021160267A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103612A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9
ES2975410T3 (es) 2020-02-13 2024-07-05 UCB Biopharma SRL Anticuerpos biespecíficos que se unen a HVEM y CD9
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
WO2021164722A1 (zh) 2020-02-21 2021-08-26 江苏恒瑞医药股份有限公司 抗il-2抗体、其抗原结合片段及其医药用途
US20230128499A1 (en) 2020-03-27 2023-04-27 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
IL296732A (en) 2020-03-27 2022-11-01 UCB Biopharma SRL Autonomous knob domain peptides
US20230176071A1 (en) 2020-05-08 2023-06-08 UCB Biopharma SRL Arrays and methods for identifying binding sites on a protein
WO2021231447A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
JP2023525060A (ja) 2020-05-14 2023-06-14 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途
EP4177274A4 (en) 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TWI888610B (zh) 2020-07-27 2025-07-01 大陸商上海拓界生物醫藥科技有限公司 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途
JP2023546071A (ja) 2020-10-13 2023-11-01 アルミラル・ソシエダッド・アノニマ 二重特異性分子およびそれを用いた処置方法
TW202231292A (zh) 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
AR124250A1 (es) 2020-12-07 2023-03-01 UCB Biopharma SRL Anticuerpos
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
GB202102227D0 (en) 2021-02-17 2021-03-31 UCB Biopharma SRL Antibodies
TW202305010A (zh) 2021-04-25 2023-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
IL308100A (en) 2021-05-03 2023-12-01 UCB Biopharma SRL Antibodies
CA3219609A1 (en) 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
JP2024523514A (ja) 2021-06-28 2024-06-28 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ４０抗体、その抗原結合断片及び医薬用途
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
KR20240046251A (ko) 2021-08-16 2024-04-08 리제너론 파아마슈티컬스, 인크. 신규 il27 수용체 효능제 및 그의 사용 방법
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
JP2024530978A (ja) 2021-08-25 2024-08-27 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 融合タンパク質を含む医薬組成物
EP4403574A4 (en) 2021-09-15 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co Ltd PD-1-Specific Protein and Its Pharmaceutical Use
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
KR20240099460A (ko) 2021-11-11 2024-06-28 리제너론 파아마슈티컬스, 인크. Cd20-pd1 결합 분자 및 이의 사용 방법
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
WO2023151661A1 (zh) 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 免疫缀合物及其用途
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
KR20250024872A (ko) 2022-05-11 2025-02-19 리제너론 파마슈티칼스 인코포레이티드 다중특이적 결합 분자 전구단백질 및 이의 용도
CA3257348A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. INTERLEUKIN-2 PROPROTEINS AND THEIR USES
CA3258187A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. INTERLEUKIN-2 PROPROTEINS AND THEIR USES
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN120051483A (zh) 2022-08-18 2025-05-27 再生元制药公司 干扰素前蛋白及其用途
EP4590335A1 (en) 2022-08-26 2025-07-30 ASLAN Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
AU2023400451A1 (en) 2022-11-28 2025-05-22 UCB Biopharma SRL Treatment of fibromyalgia
EP4634220A2 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses
US20240252601A1 (en) 2022-12-23 2024-08-01 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof
TW202432588A (zh) 2022-12-28 2024-08-16 大陸商蘇州盛迪亞生物醫藥有限公司 一種cd40結合分子的組成物及醫藥用途
IL322055A (en) 2023-01-13 2025-09-01 Regeneron Pharma IL12 receptor agonists and methods of using them
KR20250148746A (ko) 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
JP2026507123A (ja) 2023-02-28 2026-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性化剤およびその使用方法
CN121057744A (zh) 2023-02-28 2025-12-02 再生元制药公司 多价抗刺突蛋白结合分子及其用途
EP4673462A2 (en) 2023-02-28 2026-01-07 Regeneron Pharmaceuticals, Inc. Multivalent anti-spike protein binding molecules and uses thereof
KR20250156744A (ko) 2023-03-15 2025-11-03 상하이 맙젠 바이오텍 리미티드 Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도
EP4709756A1 (en) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
CN121752592A (zh) 2023-05-12 2026-03-27 再生元制药公司 干扰素受体拮抗剂及其用途
TW202508641A (zh) 2023-08-16 2025-03-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含免疫綴合物的醫藥組成物及其用途
EP4630457A1 (en) 2023-08-18 2025-10-15 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules and uses thereof
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
WO2025199243A1 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Trivalent multispecific binding molecules and methods of use thereof
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
US20250361309A1 (en) 2024-05-24 2025-11-27 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il12 receptor agonists
WO2025255480A1 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Tetravalent multispecific binding molecules and methods of use thereof
WO2025255452A2 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses thereof
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies
WO2026039791A1 (en) 2024-08-16 2026-02-19 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il2 receptor agonists
WO2026057816A1 (en) 2024-09-13 2026-03-19 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies
WO2026076013A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Tumor-targeted il2 receptor agonists and multispecific t-cell engagers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization

Also Published As

Publication number Publication date
WO2005003169A2 (en) 2005-01-13
AU2004253738A1 (en) 2005-01-13
SI1644412T2 (sl) 2018-11-30
DK1644412T4 (en) 2018-11-12
ES2551439T5 (es) 2018-11-08
CY1116913T1 (el) 2017-04-05
HUE026278T2 (en) 2016-05-30
US7989594B2 (en) 2011-08-02
EP1644412B1 (en) 2015-09-09
EP1644412A2 (en) 2006-04-12
HRP20151252T4 (hr) 2018-11-30
PL1644412T3 (pl) 2016-02-29
SI1644412T1 (sl) 2015-12-31
WO2005003169A3 (en) 2005-05-06
HRP20151252T1 (xx) 2015-12-18
PT1644412E (pt) 2015-12-23
DK1644412T3 (en) 2015-12-14
CA2527020A1 (en) 2005-01-13
US20060257394A1 (en) 2006-11-16
EP1644412B2 (en) 2018-08-08
JP2007536898A (ja) 2007-12-20
ES2551439T3 (es) 2015-11-19

Similar Documents

Publication Publication Date Title
PL1644412T5 (pl) Modyfikowane fragmenty Fab przeciwciała
PT1599504E (pt) Anticorpo modificado
IL175710A0 (en) Anti-mpl antibody
IL227753A0 (en) A qualified antibody or antibody residue
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
AU2003264009A8 (en) Humanized rabbit antibodies
GB0426043D0 (en) Antibodies
PL375405A1 (pl) Przeciwciała
IL176940A (en) An isolated antibody or antigen-binding fragment thereof
EP1648512A4 (en) ANTI-CD19 ANTIBODIES
AU2003217912A8 (en) Antibody optimization
PT3085783T (pt) Anticorpo biespecífico substituinte de proteínas funcionais
GB0305702D0 (en) Bispecific antibodies
TWI346203B (en) Antibody pair screening methods
IL173557A0 (en) Variable antibodies
EP1631315A4 (en) ANTIBODIES BINDING TO HUMAN CXCR3
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
EP1677112A4 (en) IMMUNE TEST
GB0305448D0 (en) Immunoassay
AU2003275834A1 (en) ANTIBODIES THAT BIND alphaE INTEGRIN
GB0306618D0 (en) Antibody
WO2006138429A3 (en) Antibodies against hmgb1 and fragments thereof
GB0226878D0 (en) Antibodies
GB0302699D0 (en) Immunoglobulin
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin